Trial Profile
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia) for Crohn's Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2023
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms SECURE
- Sponsors UCB; UCB Biosciences
- 09 May 2023 Results of post-hoc analysis of data from the SECURE registry assessing the long term real world pregnancy outcomes of patients exposed to CZP versus those exposed to other CD treatments presented at the Digestive Disease Week 2023
- 23 May 2021 Results of post hoc analysis assessing the non-melanoma skin cancer risk by incidence rate ratio in patients with crohns disease, presented at the Digestive Disease Week 2021.
- 28 Sep 2020 Status changed from active, no longer recruiting to completed.